* Atea Pharmaceuticals Inc reported a quarterly adjusted loss of 47 cents per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of four analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -52 cents to -48 cents per share.
* Reported revenue was zero; analysts expected zero.
* Atea Pharmaceuticals Inc's reported EPS for the quarter was a loss of 47 cents.
* The company reported a quarterly loss of $38.7 million.
* Atea Pharmaceuticals Inc shares had risen by 49.5% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 2.8% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $3.00 This summary was machine generated from LSEG data February 29 at 02:26 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.50 -0.47 Beat
Sep. 30 2023 -0.48 -0.40 Beat
Jun. 30 2023 -0.47 -0.34 Beat
Mar. 31 2023 -0.48 -0.43 Beat
Comments